Clinical Trial Update: A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs [Phase 2]

View source ↗

Summary

Phase II trial evaluating camrelizumab plus apatinib as neoadjuvant therapy for early-stage triple-negative breast cancer with high tumor-infiltrating lymphocyt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Breast Cancer, Triple-Negative Breast Cancer | Phase 2 | Status: UNKNOWN